Weill Cornell’s Dr. Ari Melnick on BCL6 Inhibitor Research: Implications for Lymphoma Research

Ari Melnick, MD, director of the Melnick Lab at Weill Cornell Medical College, was interviewed by the Lymphoma Research Foundation about his breakthrough research on a BCL6 inhibitor. Dr. Melnick discusses why this study is important for patients and what it could mean for the future of lymphoma research.

Click on the image below to read the Q&A.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s